Curcumin triggers DNA damage and inhibits expression of DNA repair proteins in human lung cancer cells

Anticancer Research

Volumn 35, Issue 7, 2015, Pages 3867-3874

  Ting, Chien Yi ^a,b   Wang, Hsin Ell ^a   Yu, Chien Chih ^c   Liu, Hsin Chung ^c   Liu, Yu Chang ^a   Chiang, I Tsang ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b SHU ZEN JUNIOR COLLEGE OF MEDICINE AND MANAGEMENT   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Curcumin; DNA damage; DNA repair; Human lung cancer

Indexed keywords

BRCA1 PROTEIN; CURCUMIN; DNA REPAIR PROTEIN; HISTONE H2AX; MEDIATOR OF DNA DAMAGE CHECKPOINT 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NUCLEIC ACID BINDING PROTEIN; PROTEIN P53; STRATIFIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; DRUG EFFECTS; GENETICS; LUNG TUMOR; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CURCUMIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84937109884     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227, 2002.
2. Ding J, Miao ZH, Meng LH and Geng MY: Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci 27: 338-344, 2006.
3. Zhou BB and Bartek J: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4: 216-225, 2004.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
5. Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y and Wang D: Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol 74: 777-786, 2014.
6. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ and Maestre J: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13: 2443-2449, 2004.
7. Shehzad A and Lee YS: Molecular mechanisms of curcumin action: signal transduction. BioFactors 39: 27-36, 2013.
8. Ogiwara H, Ui A, Shiotani B, Zou L, Yasui A and Kohno T: Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. Carcinogenesis 34: 2486-2497, 2013.
9. Wang WH, Chiang IT, Ding K, Chung JG, Lin WJ, Lin SS and Hwang JJ: Curcumin-induced apoptosis in human hepatocellular carcinoma j5 cells: critical role of Ca(+2)-dependent pathway. Evid Based Complement Alternat Med 2012: 512907, 2012.
10. Lin SS, Huang HP, Yang JS, Wu JY, Hsia TC, Lin CC, Lin CW, Kuo CL, Gibson Wood W and Chung JG: DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade- and mitochondrial-dependent pathway. Cancer Lett 272: 77-90, 2008.
11. Hsia TC, Lin JH, Hsu SC, Tang NY, Lu HF, Wu SH, Lin JG and Chung JG: Cantharidin induces DNA damage and inhibits DNA repair-associated protein levels in NCI-H460 human lung cancer cells. Environ Toxicol 2014.
12. Wu SH, Hang LW, Yang JS, Chen HY, Lin HY, Chiang JH, Lu CC, Yang JL, Lai TY, Ko YC and Chung JG: Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res 30: 2125-2133, 2010.
13. Howells LM, Mahale J, Sale S, McVeigh L, Steward WP, Thomas A and Brown K: Translating curcumin to the clinic for lung cancer prevention: evaluation of the preclinical evidence for its utility in primary, secondary and tertiary prevention strategies. J Pharmacol Exp Ther 350: 483-494, 2014.
14. Zhu Y, Hu J, Hu Y and Liu W: Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. Cancer Treat Rev 35: 590-596, 2009.
15. Shiba-Ishii A, Kano J, Morishita Y, Sato Y, Minami Y and Noguchi M: High expression of stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma. Int J Cancer 129: 2445-2453, 2011.
16. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, Califano JA, Goodman SN, Westra WH, Hoque MO and Sidransky D: An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res 17: 4494-4503, 2011.
17. Choi CM, Yang SC, Jo HJ, Song SY, Jeon YJ, Jang TW, Kim DJ, Jang SH, Yang SH, Kim YD, Lee KH, Jang SJ, Kim YT, Kim DK, Chung DH, Kim L, Nam HS, Cho JH, Kim HJ and Ryu JS: Proteins involved in DNA damage-response pathways and survival of stage I non-small-cell lung cancer patients. Ann Oncol 23: 2088-2093, 2012.
18. Tsai MS, Weng SH, Kuo YH, Chiu YF and Lin YW: Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Mol Pharmacol 80: 136-146, 2011.
19. Lakin ND and Jackson SP: Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655, 1999.
20. Sharma A, Singh K and Almasan A: Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 920: 613-626, 2012.
21. Pabla N, Huang S, Mi QS, Daniel R and Dong Z: ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283: 6572-6583, 2008.